Illumina (NASDAQ:ILMN) Insider Scott Davies Sells 615 Shares

Illumina, Inc. (NASDAQ:ILMN) insider Scott Davies sold 615 shares of the firm’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $180.00, for a total value of $110,700.00. Following the completion of the sale, the insider directly owned 20,953 shares in the company, valued at $3,771,540. This trade represents a 2.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Illumina Stock Up 1.5%

Shares of NASDAQ ILMN opened at $177.65 on Friday. The company has a market cap of $26.88 billion, a price-to-earnings ratio of 32.30, a PEG ratio of 3.28 and a beta of 1.50. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56. Illumina, Inc. has a 12 month low of $88.00 and a 12 month high of $182.84. The stock has a 50-day moving average price of $148.74 and a two-hundred day moving average price of $137.38.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The company had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same period last year, the company posted $0.97 EPS. The firm’s quarterly revenue was up 4.8% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, analysts forecast that Illumina, Inc. will post 5.21 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of ILMN. Elyxium Wealth LLC bought a new stake in Illumina during the fourth quarter valued at $25,000. Board of the Pension Protection Fund bought a new position in shares of Illumina in the 4th quarter worth about $26,000. Creative Capital Management Investments LLC lifted its stake in shares of Illumina by 160.0% in the 4th quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock valued at $26,000 after purchasing an additional 120 shares during the period. TD Waterhouse Canada Inc. acquired a new position in shares of Illumina in the 4th quarter valued at about $26,000. Finally, Laurel Wealth Advisors LLC bought a new stake in shares of Illumina during the 4th quarter valued at about $26,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analysts Set New Price Targets

ILMN has been the subject of several recent research reports. Citigroup upped their price objective on Illumina from $80.00 to $95.00 and gave the company a “sell” rating in a research note on Monday, May 4th. Royal Bank Of Canada began coverage on shares of Illumina in a report on Thursday, May 14th. They set an “outperform” rating and a $170.00 target price on the stock. Barclays upped their price target on shares of Illumina from $122.00 to $145.00 and gave the company an “underweight” rating in a research report on Wednesday. Evercore reiterated an “outperform” rating on shares of Illumina in a report on Friday, May 1st. Finally, JPMorgan Chase & Co. raised shares of Illumina from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $125.00 to $185.00 in a research note on Wednesday, June 10th. Eight research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Illumina has an average rating of “Hold” and a consensus target price of $143.56.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.